Cabaletta Bio (NASDAQ: CABA) is a clinical-stage biotechnology company dedicated to discovering and developing T cell therapies for B cell-mediated autoimmune diseases. Their proprietary Chimeric AutoAntibody Receptor (CAAR) T cell technology aims to selectively eliminate B cells that produce disease-causing autoantibodies. Their lead product candidate, CABA-201, a 4-1BB-containing fully human CD19-CAR T therapy, is being evaluated for various autoimmune conditions including systemic lupus erythematosus, myositis, generalized myasthenia gravis, and systemic sclerosis.
Serves as the primary center for Cabaletta Bio's research and development, clinical operations, strategic planning, and corporate administration.
The headquarters is located in a modern office building in Philadelphia's University City district, providing advanced laboratory and office facilities designed to support scientific research and collaboration.
Cabaletta Bio fosters a science-driven, innovative, and collaborative work environment. The culture emphasizes patient-centricity, teamwork, and a commitment to scientific excellence in developing transformative therapies.
Its Philadelphia location provides strategic access to a rich ecosystem of academic institutions, research organizations, talent, and potential collaborators in the biotechnology and pharmaceutical sectors.
Cabaletta Bio is primarily based in the United States, with its headquarters in Philadelphia, PA. While its core operations are U.S.-centric, its clinical trials for product candidates like CABA-201 may involve multiple sites nationally and potentially internationally, collaborating with research institutions and clinical centers to advance its therapeutic programs for patients with autoimmune diseases.
2929 Arch Street, Suite 600
Philadelphia
PA
USA
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Cabaletta Bio' leadership includes:
Cabaletta Bio has been backed by several prominent investors over the years, including:
Over the past 12 months, Cabaletta Bio has strengthened its executive team with key appointments, including a new Chief Financial Officer, Chief People Officer, and Chief Medical Officer, alongside a significant promotion for its head of R&D. These changes support the company's growth and advancement of its clinical pipeline.
Discover the tools Cabaletta Bio uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Cabaletta Bio commonly uses the email format where the first initial is followed by the last name, such as 'jdoe@cabalettabio.com'. This is a prevalent pattern among employees for official communications.
[first_initial][last]@cabalettabio.com
Format
snichtberger@cabalettabio.com
Example
85%
Success rate
GlobeNewswire • May 9, 2024
Cabaletta Bio announced its Q1 2024 financial results, provided updates on its CABA-201 clinical program for lupus and myositis, noted IND clearance for CABA-201 in generalized myasthenia gravis, and announced the promotion of Gwendolyn Binder, Ph.D., to President, Science and Technology....more
GlobeNewswire • March 11, 2024
David J. Chang, M.D., M.P.H. was appointed as Cabaletta Bio's new Chief Medical Officer to lead the company's clinical development and medical affairs strategy....more
GlobeNewswire • February 15, 2024
The U.S. Food and Drug Administration (FDA) cleared Cabaletta Bio's Investigational New Drug (IND) application for CABA-201, allowing the initiation of a Phase 1/2 clinical trial for patients with systemic sclerosis....more
GlobeNewswire • December 4, 2023
Heather Attra joined Cabaletta Bio as Chief People Officer, bringing extensive experience in human resources and talent management within the life sciences industry to lead the company's people strategy....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Cabaletta Bio, are just a search away.